Etoposide hypersensitivity
Yersal, O.; Barutca, S.; Meydan, N.
Journal of BUON Official Journal of the Balkan Union of Oncology 18(2): 547-548
2013
ISSN/ISBN: 1107-0625 PMID: 23818380 Document Number: 665292
Document emailed within 1 workday
Related Documents
Hande, K.; Anthony, L.; Hamilton, R.; Bennett, R.; Sweetman, B.; Branch, R. 1988: Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit Cancer Research 48(7): 1829-1834Hagiwara, A.; Takahashi, T.; Sawai, K.; Seiki, K.; Ito, M.; Okano, S.; Sakakura, C.; Shobayashi, S.; Muranishi, S.; Tomoda, H. 1992: Enhanced therapeutic efficacy of intralymph-nodal etoposide on distal lymph node metastases using a new dosage format--activated carbon particles adsorbing etoposide Anti-Cancer Drug Design 7(2): 163-168
Yuki, K.; Kodama, Y.; Emoto, K.; Yukawa, O.; Onda, J.; Uozumi, T. 1989: A case report of advanced malignant mixed germ cell tumor of parasellar origin indicating marked efficacy of a salvage combined chemotherapy of CDDP and etoposide and subsequent chemotherapy using oral etoposide Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(8 Pt 1): 2651-2654
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Stashenko, P.P.; Bhan, A.K.; Schlossman, S.F.; Mccluskey, R.T. 1977: Local transfer of delayed hypersensitivity and cutaneous basophil hypersensitivity Journal of Immunology 119(6): 1987-1993
Neta, R.; Salvin, S.B. 1974: Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity Journal of Immunology 113(6): 1716-1725
Fleming, R.A.; Miller, A.A.; Stewart, C.F. 1989: Etoposide: an update Clinical Pharmacy 8(4): 274-293
D'Incalci, M.; Sessa, C.; Rossi, C.; Roviaro, G.; Mangioni, C. 1985: Pharmacokinetics of etoposide in gestochoriocarcinoma Cancer Treatment Reports 69(1): 69-72
Macdonald, J.S.; Havlin, K.A. 1992: Etoposide in gastric cancer Seminars in Oncology 19(6 Suppl 13: 59-62
Kanazawa, K.; Moromizato, H. 1996: Etoposide (VP-16) in gynecologic malignancy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(14): 1925-1928
Alvarez Cardona, Aóteles.; Hernández Nieto, L.; Pérez Gómez, Mín.; Pedroza Meléndez, A.; Huerta López, Jé.G. 2010: Etoposide desensitization. A case report Revista Alergia Mexico 57(1): 33-36
Meresse, P.; Dechaux, E.; Monneret, C.; Bertounesque, E. 2004: Etoposide: discovery and medicinal chemistry Current Medicinal Chemistry 11(18): 2443-2466
Young, R.C. 1992: Etoposide in the treatment of non-Hodgkin's lymphomas Seminars in Oncology 19(6 Suppl 13: 19-25
Brooks, D.J.; Alberts, D.S. 1996: A phase i study of etoposide phosphate plus paclitaxel Seminars in Oncology 23(6 Suppl 13: 30-33
Wong, L.C.; Choo, Y.C.; Ma, H.K. 1984: Oral etoposide in gestational trophoblastic disease Cancer Treatment Reports 68(5): 775-777
Taguchi, A.; Takeshita, S.; Machida, R.; Hori, Y.; Aida, K.; Furuya, U.; Ohe, E.; Murase, T.; Shinozuka, N.; Ayabe, T.; Mori, H. 2003: Anaphylaxia induced by etoposide--a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(8): 1187-1189
Nichols, C.R. 1992: Role of etoposide in treatment of breast cancer Seminars in Oncology 19(6 Suppl 13: 67-71
Seeber, S.; Osieka, R.; Schmidt, C.G.; Achterrath, W.; Crooke, S.T. 1982: In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II) Cancer Research 42(11): 4719-4725
Helson, L. 1986: Cis-platinum (CDDP) plus etoposide (VP-16-213) and treatment of disseminated neuroblastoma Anticancer Research 6(6): 1337-1340